Steve Avery, Jamie M. Buske, Doris Chen, Herman Chen, Xin Chen, Andrew R. Davidson, Jean-Nicolas Desrosiers, Hanqing Dong*, Noalle Fellah, David F. Fernández*, John Grosso, Lu Han, Teri Hochdorfer, Amber M. Johnson, Brian P. Jones, Maciej Kalinowski, Katherine D. Launer-Felty, Jorge Lopez, Teresa Makowski, Carolyn Mastriano, Truong N. Nguyen, Nitinchandra D. Patel, Zhihui Peng*, Tyler Potter, Robert P. Pritchard, Anil M. Rane, Max Reeve, Margaret C. Richins, Chase A. Salazar, John J. Salisbury, Robert Simpson*, Liza Tabshey, Erin J. Tweed, Paul G. Wahome, Nancy Walsh-Sayles, Jordan A. Willie and Ethan Wood,
{"title":"开发用于治疗乳腺癌的口服生物型 PROTAC 雌激素受体降解剂 Vepdegestrant 的商业制造工艺","authors":"Steve Avery, Jamie M. Buske, Doris Chen, Herman Chen, Xin Chen, Andrew R. Davidson, Jean-Nicolas Desrosiers, Hanqing Dong*, Noalle Fellah, David F. Fernández*, John Grosso, Lu Han, Teri Hochdorfer, Amber M. Johnson, Brian P. Jones, Maciej Kalinowski, Katherine D. Launer-Felty, Jorge Lopez, Teresa Makowski, Carolyn Mastriano, Truong N. Nguyen, Nitinchandra D. Patel, Zhihui Peng*, Tyler Potter, Robert P. Pritchard, Anil M. Rane, Max Reeve, Margaret C. Richins, Chase A. Salazar, John J. Salisbury, Robert Simpson*, Liza Tabshey, Erin J. Tweed, Paul G. Wahome, Nancy Walsh-Sayles, Jordan A. Willie and Ethan Wood, ","doi":"10.1021/acs.oprd.4c0036210.1021/acs.oprd.4c00362","DOIUrl":null,"url":null,"abstract":"<p >A commercial process for vepdegestrant (<b>1</b>), the most advanced PROTAC protein degrader in human clinical trials, has been developed to support clinical and commercial needs. The process features an efficient convergent synthetic strategy through the final reductive amination of two advanced chiral intermediates, as well as several highly efficient telescoped processes and robust crystallization for purity control. The final commercial process of vepdegestrant (<b>1</b>) consists of seven proposed regulatory GMP steps with five isolations in an overall yield of 29%.</p>","PeriodicalId":55,"journal":{"name":"Organic Process Research & Development","volume":"28 11","pages":"4079–4090 4079–4090"},"PeriodicalIF":3.1000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer\",\"authors\":\"Steve Avery, Jamie M. Buske, Doris Chen, Herman Chen, Xin Chen, Andrew R. Davidson, Jean-Nicolas Desrosiers, Hanqing Dong*, Noalle Fellah, David F. Fernández*, John Grosso, Lu Han, Teri Hochdorfer, Amber M. Johnson, Brian P. Jones, Maciej Kalinowski, Katherine D. Launer-Felty, Jorge Lopez, Teresa Makowski, Carolyn Mastriano, Truong N. Nguyen, Nitinchandra D. Patel, Zhihui Peng*, Tyler Potter, Robert P. Pritchard, Anil M. Rane, Max Reeve, Margaret C. Richins, Chase A. Salazar, John J. Salisbury, Robert Simpson*, Liza Tabshey, Erin J. Tweed, Paul G. Wahome, Nancy Walsh-Sayles, Jordan A. Willie and Ethan Wood, \",\"doi\":\"10.1021/acs.oprd.4c0036210.1021/acs.oprd.4c00362\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >A commercial process for vepdegestrant (<b>1</b>), the most advanced PROTAC protein degrader in human clinical trials, has been developed to support clinical and commercial needs. The process features an efficient convergent synthetic strategy through the final reductive amination of two advanced chiral intermediates, as well as several highly efficient telescoped processes and robust crystallization for purity control. The final commercial process of vepdegestrant (<b>1</b>) consists of seven proposed regulatory GMP steps with five isolations in an overall yield of 29%.</p>\",\"PeriodicalId\":55,\"journal\":{\"name\":\"Organic Process Research & Development\",\"volume\":\"28 11\",\"pages\":\"4079–4090 4079–4090\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2024-11-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Organic Process Research & Development\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acs.oprd.4c00362\",\"RegionNum\":3,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, APPLIED\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Organic Process Research & Development","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.oprd.4c00362","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}
Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer
A commercial process for vepdegestrant (1), the most advanced PROTAC protein degrader in human clinical trials, has been developed to support clinical and commercial needs. The process features an efficient convergent synthetic strategy through the final reductive amination of two advanced chiral intermediates, as well as several highly efficient telescoped processes and robust crystallization for purity control. The final commercial process of vepdegestrant (1) consists of seven proposed regulatory GMP steps with five isolations in an overall yield of 29%.
期刊介绍：
The journal Organic Process Research & Development serves as a communication tool between industrial chemists and chemists working in universities and research institutes. As such, it reports original work from the broad field of industrial process chemistry but also presents academic results that are relevant, or potentially relevant, to industrial applications. Process chemistry is the science that enables the safe, environmentally benign and ultimately economical manufacturing of organic compounds that are required in larger amounts to help address the needs of society. Consequently, the Journal encompasses every aspect of organic chemistry, including all aspects of catalysis, synthetic methodology development and synthetic strategy exploration, but also includes aspects from analytical and solid-state chemistry and chemical engineering, such as work-up tools，process safety, or flow-chemistry. The goal of development and optimization of chemical reactions and processes is their transfer to a larger scale; original work describing such studies and the actual implementation on scale is highly relevant to the journal. However, studies on new developments from either industry, research institutes or academia that have not yet been demonstrated on scale, but where an industrial utility can be expected and where the study has addressed important prerequisites for a scale-up and has given confidence into the reliability and practicality of the chemistry, also serve the mission of OPR&D as a communication tool between the different contributors to the field.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
